260 related articles for article (PubMed ID: 18834890)
1. Structural evidence for effectiveness of darunavir and two related antiviral inhibitors against HIV-2 protease.
Kovalevsky AY; Louis JM; Aniana A; Ghosh AK; Weber IT
J Mol Biol; 2008 Dec; 384(1):178-92. PubMed ID: 18834890
[TBL] [Abstract][Full Text] [Related]
2. Origin of decrease in potency of darunavir and two related antiviral inhibitors against HIV-2 compared to HIV-1 protease.
Kar P; Knecht V
J Phys Chem B; 2012 Mar; 116(8):2605-14. PubMed ID: 22280246
[TBL] [Abstract][Full Text] [Related]
3. Revealing origin of decrease in potency of darunavir and amprenavir against HIV-2 relative to HIV-1 protease by molecular dynamics simulations.
Chen J; Liang Z; Wang W; Yi C; Zhang S; Zhang Q
Sci Rep; 2014 Nov; 4():6872. PubMed ID: 25362963
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis for substrate recognition and drug resistance from 1.1 to 1.6 angstroms resolution crystal structures of HIV-1 protease mutants with substrate analogs.
Tie Y; Boross PI; Wang YF; Gaddis L; Liu F; Chen X; Tozser J; Harrison RW; Weber IT
FEBS J; 2005 Oct; 272(20):5265-77. PubMed ID: 16218957
[TBL] [Abstract][Full Text] [Related]
5. Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.
Wang YF; Tie Y; Boross PI; Tozser J; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2007 Sep; 50(18):4509-15. PubMed ID: 17696515
[TBL] [Abstract][Full Text] [Related]
6. High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.
Tie Y; Boross PI; Wang YF; Gaddis L; Hussain AK; Leshchenko S; Ghosh AK; Louis JM; Harrison RW; Weber IT
J Mol Biol; 2004 Apr; 338(2):341-52. PubMed ID: 15066436
[TBL] [Abstract][Full Text] [Related]
7. Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.
Liu F; Kovalevsky AY; Tie Y; Ghosh AK; Harrison RW; Weber IT
J Mol Biol; 2008 Aug; 381(1):102-15. PubMed ID: 18597780
[TBL] [Abstract][Full Text] [Related]
8. Substituted Bis-THF Protease Inhibitors with Improved Potency against Highly Resistant Mature HIV-1 Protease PR20.
Agniswamy J; Louis JM; Shen CH; Yashchuk S; Ghosh AK; Weber IT
J Med Chem; 2015 Jun; 58(12):5088-95. PubMed ID: 26010498
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors.
Skulnick HI; Johnson PD; Howe WJ; Tomich PK; Chong KT; Watenpaugh KD; Janakiraman MN; Dolak LA; McGrath JP; Lynn JC
J Med Chem; 1995 Dec; 38(26):4968-71. PubMed ID: 8544171
[No Abstract] [Full Text] [Related]
10. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
[TBL] [Abstract][Full Text] [Related]
11. Revealing the dimer dissociation and existence of a folded monomer of the mature HIV-2 protease.
Louis JM; Ishima R; Aniana A; Sayer JM
Protein Sci; 2009 Dec; 18(12):2442-53. PubMed ID: 19798742
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir.
Sasková KG; Kozísek M; Rezácová P; Brynda J; Yashina T; Kagan RM; Konvalinka J
J Virol; 2009 Sep; 83(17):8810-8. PubMed ID: 19535439
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters.
Shen CH; Wang YF; Kovalevsky AY; Harrison RW; Weber IT
FEBS J; 2010 Sep; 277(18):3699-714. PubMed ID: 20695887
[TBL] [Abstract][Full Text] [Related]
15. Critical differences in HIV-1 and HIV-2 protease specificity for clinical inhibitors.
Tie Y; Wang YF; Boross PI; Chiu TY; Ghosh AK; Tozser J; Louis JM; Harrison RW; Weber IT
Protein Sci; 2012 Mar; 21(3):339-50. PubMed ID: 22238126
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.
Kovalevsky AY; Tie Y; Liu F; Boross PI; Wang YF; Leshchenko S; Ghosh AK; Harrison RW; Weber IT
J Med Chem; 2006 Feb; 49(4):1379-87. PubMed ID: 16480273
[TBL] [Abstract][Full Text] [Related]
17. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
[TBL] [Abstract][Full Text] [Related]
18. Unexpected binding mode of a cyclic sulfamide HIV-1 protease inhibitor.
Bäckbro K; Löwgren S; Osterlund K; Atepo J; Unge T; Hultén J; Bonham NM; Schaal W; Karlén A; Hallberg A
J Med Chem; 1997 Mar; 40(6):898-902. PubMed ID: 9083478
[TBL] [Abstract][Full Text] [Related]
19. Enamino-oxindole HIV protease inhibitors.
Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
[TBL] [Abstract][Full Text] [Related]
20. Structures of darunavir-resistant HIV-1 protease mutant reveal atypical binding of darunavir to wide open flaps.
Zhang Y; Chang YC; Louis JM; Wang YF; Harrison RW; Weber IT
ACS Chem Biol; 2014 Jun; 9(6):1351-8. PubMed ID: 24738918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]